Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018
Favorable Tolerability Profile and Early Signs of Efficacy Demonstrated
First Disclosure of Clinical Data from Novel Dolaflexin Platform
Mersana To Host Conference Call and Webcast Including Principal Investigator,
“We are highly encouraged by these first clinical data from our novel Dolaflexin platform demonstrating a favorable safety and tolerability profile and early signs of efficacy for XMT-1522 in heavily pre-treated patients who have exhausted available therapies,” said Anna Protopapas, President and CEO,
In a poster titled “Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric tumors,” Mersana demonstrated that as of
Mersana will host a conference call and webcast including principal investigator,
About XMT-1522
XMT-1522 is a Dolaflexin ADC targeting HER2-expressing tumors. XMT-1522 comprises a proprietary HER2 antibody which is conjugated with Mersana’s Dolaflexin platform – a Fleximer polymer linked with a proprietary auristatin payload. XMT-1522 provides a drug load of approximately 12 molecules per antibody, specifically designed to improve potency while simultaneously increasing tolerability. XMT-1522 has the potential to extend HER2-targeted therapy beyond the current “HER2-positive” populations into patients with lower levels of HER2 expression. The Phase 1 protocol will evaluate XMT-1522 in patients with advanced HER2-positive breast and gastric cancer, as well as advanced breast cancer with low HER2 expression and non-small cell lung cancer. More information on the ongoing Phase 1 clinical study can be found at clinicaltrials.gov.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of federal securities laws. These are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially. These risks are discussed in the Company’s SEC filings including, without limitation, the Company’s Annual Report on Form 10-K filed on March 28, 2018. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
Media Contact
pkidwell@mersana.com
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
christina@sternir.com
(212) 362-1200
Source: Mersana Therapeutics, Inc.